[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639752":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":34,"centralContacts":37,"locations":43,"responsibleParty":65,"collaborators":34,"id":67,"slug":34,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":34,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":34,"enrollmentInfo":75,"targetDuration":34,"studyType":78,"phases":79,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":58,"whyStopped":34,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Hyundai Bioscience Co., Ltd.","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"CP-COV03 low dose","EXPERIMENTAL","450 mg\u002Fday",[13],"Drug: CP-COV03",{"label":15,"type":10,"description":16,"interventionNames":17},"CP-COV03 mid dose","900 mg\u002Fday",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"CP-COV03 high dose","1,350 mg\u002Fday",[13],{"label":23,"type":24,"description":25,"interventionNames":26},"Placebo","PLACEBO_COMPARATOR","Matching placebo",[27],"Drug: Placebo",[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","CP-COV03","Oral administration",[19,9,15],null,{"type":30,"name":23,"description":32,"armGroupLabels":36,"otherNames":34},[23],[38],{"name":39,"role":40,"phone":41,"phoneExt":34,"email":42},"Central Contact Person","CONTACT","+82-1544-3194","clinical@hyundaibio.com",[44,56],{"facility":45,"status":46,"city":47,"state":34,"zip":34,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":34},"The National Hospital of Tropical Diseases (NHTD)","NOT_YET_RECRUITING","Hanoi","Vietnam","VN",{"type":51,"coordinates":52},"Point",[53,54],105.84117,21.0245,{"lat":54,"lon":53},{"facility":57,"status":58,"city":59,"state":34,"zip":34,"country":48,"countryCode":49,"cosmosGeoPoint":60,"geoPoint":64,"contacts":34},"Tien Giang Provincial General Hospital","RECRUITING","Mỹ Tho",{"type":51,"coordinates":61},[62,63],106.35996,10.36004,{"lat":63,"lon":62},{"type":66,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100639752",false,"NCT07576868","A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)","A Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate Safety and Efficacy of CP-COV03 in Dengue Patients (Part 1) \u002F Dengue and Dengue-like Illness Patients (Part 2)","Inclusion Criteria:\n\n* Patients who are 18 years or over of age at time of screening.\n* Patients who have at least two symptoms with a score of 2 or higher within 72 h from fever onset.\n* Patients who are diagnosed with dengue by NS1 positive (Phase 2- Part 1 only). And patients who are classified as dengue, zika, influenza, COVID-19 and others (Phase 3- Part 2 only)\n\nExclusion Criteria:\n\n* Patients who show severe dengue (WHO dengue guideline C, any severe symptoms or clinical laboratory results)\n* Patients who have previously received dengue vaccine\n* Patients who have chronic medical conditions such as uncontrolled diabetes mellitus, severe asthma requiring oral steroids or admission to the hospital in the previous 6 months for cardiac disease","ALL","18 Years",{"count":76,"type":77},210,"ESTIMATED","INTERVENTIONAL",[80,81],"PHASE2","PHASE3","This is a randomized, double-blind, placebo-controlled Phase 2\u002F3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.",[84],"Dengue",[86,87,88],"dengue","dengue treatment","dengue antiviral","2026-05-04",{"date":91,"type":92},"2026-05-08","ACTUAL",{"date":94,"type":92},"2026-04-09",{"date":96,"type":77},"2027-05",{"name":5,"class":6},2]